# Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC

> **NCT06904014** · PHASE2 · RECRUITING · sponsor: **Lei ZHAO** · enrollment: 40 (estimated)

## Conditions studied

- HCC

## Interventions

- **PROCEDURE:** HAIC
- **DRUG:** Sintilimab
- **DRUG:** Lenvatinib
- **PROCEDURE:** surgery

## Key facts

- **NCT ID:** NCT06904014
- **Lead sponsor:** Lei ZHAO
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-25
- **Primary completion:** 2027-06-30
- **Final completion:** 2029-06-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06904014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06904014, "Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06904014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*